Eli Lilly's new weight loss pill Orforglipron only gave 11.2 percent weight loss, shows new study results from a phase 3 study. It was below expectations for the preparation and the stock plummets 14 percent in American trading. Previously, the hope has been that the pill will be as effective as Novo Nordisk's bestseller Wegovy, writes Bloomberg.
Common side effects of the preparation were also, among other things, nausea, vomiting and diarrhea. If the weight loss pill is approved, it may be on the market next year.
Shortly after the study miss, Eli Lilly reports figures for the second quarter that beat expectations, including continued strong demand for Eli Lilly's weight loss preparations Zepbound and Mounjaro. The company is also raising its forecasts for the full year 2025. The strong report, however, does not help the stock, which continues to plummet.
Danish sector colleague Novo Nordisk surges 12 percent on the Copenhagen Stock Exchange after the competitor's study results. It is the stock's sharpest rise in four months, writes Bloomberg. Novo Nordisk's stock, which has been partly weighed down by the increased competition in the sector, is now only down 48 percent since the turn of the year.
